Lipid CA2d
Instructions for Use
Product information
CA2d is an ionizable lipid developed for systemic mRNA delivery to the central nervous system. Its architecture combines an MK-0752-derived CNS-accessing moiety, a short three-carbon diamine spacer, a tertiary ionizable amine, and two acetal-containing hydrophobic tails. When formulated with DOPE, cholesterol and DMG-PEG2000, CA2d LNPs crossed the blood-brain barrier through caveolae- and γ-secretase-associated transcytosis and delivered mRNA to neurons, astrocytes, microglia and brain endothelial cells. Following intravenous administration of FLuc mRNA at 0.5 mg/kg in mice, CA2d produced 16.6-fold higher brain expression than MC3 and 8.6-fold higher expression than SM-102 at 6 hours. CA2d was further evaluated in repeated brain-cell transfection studies, a pilot rhesus macaque experiment and a tPA-modified TGF-β1 mRNA formulation for ischemic stroke. These results support CA2d as a promising preclinical research lipid for investigating non-viral CNS mRNA delivery; it has not been clinically validated.
| CAS No. | Not available |
| Chemical Name | Lipid CA2d |
| Formula | Not available |
| M.Wt | Not available |
| Purity | >98% |
| Storage | Original product: up to 1 year under the storage conditions stated on the vial, kept tightly sealed. Stock solutions: aliquots at -20°C, generally up to one month. |
| Shipping condition | Ships from Shanghai. Pure lipid is stable during ice-pack transport. |
Formulation & study context
Literature information refers to the cited study and its particular formulation. Administration routes are research context, not clinical instructions or a guarantee of performance.
A complete product-specific formulation has not been verified. No standard ratio is substituted.
| N/P ratio | Not reported in the verified record |
| Cargo | Not available in the verified record |
| Administration route | Not available in the verified record |
| Animal model | Not available in the verified record |
| Formulation process | Not available in the verified record |
N/P is the molar ratio of specified lipid nitrogen groups to nucleic-acid phosphate groups. A lipid:cargo mass ratio is a different quantity and must not be used as N/P.
Stock-solution preparation table
Calculated from the product-page molecular weight: not available g/mol. Volumes are final solution volumes.
| Lipid mass | 1 mM | 5 mM | 10 mM |
|---|---|---|---|
| 10 mg | MW unavailable | MW unavailable | MW unavailable |
| 25 mg | MW unavailable | MW unavailable | MW unavailable |
| 50 mg | MW unavailable | MW unavailable | MW unavailable |
| 100 mg | MW unavailable | MW unavailable | MW unavailable |
| 250 mg | MW unavailable | MW unavailable | MW unavailable |
Volume (mL) = mass (mg) × 1000 / [MW (g/mol) × concentration (mM)]. These are mathematical conversions, not measured solubility or validated solvent recommendations. Confirm solvent compatibility and the molecular weight of the exact material before use.
Open editable solution calculators →Handling & storage
Provided that storage conditions are as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to 1 year.
Wherever possible, prepare and use solutions on the same day. If stock solutions must be prepared in advance, store them as aliquots in tightly sealed vials at -20°C. Generally, these will be usable for up to one month.
Before use, and prior to opening the vial, allow the product to equilibrate to room temperature for at least 1 hour.
References
Wang S, Zhong Y, Wang C, Tian M, Bennett JL, Bliss-Moreau E, Xue Y, Yu C, Hou X, Zheng YY, Li H, Liu Z, Cao D, Kang DD, Deng B, Dong Y. Overcoming the blood-brain barrier using central nervous system-accessing lipid nanoparticles for enhanced mRNA therapeutics. Proc Natl Acad Sci U S A. 2026 Aug 18;123(33):e2538147123. doi: 10.1073/pnas.2538147123. Epub 2026 Aug 14. PMID: 42599788.